These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21314021)

  • 21. [Should Hepatitis C be treated? Objectives of antiviral treatments in hepatitis C virus infection].
    Degos F
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S57-65. PubMed ID: 9161515
    [No Abstract]   [Full Text] [Related]  

  • 22. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 24. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapeutic options for hepatitis C.
    Waters L; Nelson M
    Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
    Bader T
    J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
    Berenguer M; Wright TL
    Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating hepatitis C in lower-income countries.
    Jayasekera CR; Barry M; Roberts LR; Nguyen MH
    N Engl J Med; 2014 May; 370(20):1869-71. PubMed ID: 24720680
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular biology of hepatitis C infection.
    Drazan KE
    Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.
    McGuigan C; Gilles A; Madela K; Aljarah M; Holl S; Jones S; Vernachio J; Hutchins J; Ames B; Bryant KD; Gorovits E; Ganguly B; Hunley D; Hall A; Kolykhalov A; Liu Y; Muhammad J; Raja N; Walters R; Wang J; Chamberlain S; Henson G
    J Med Chem; 2010 Jul; 53(13):4949-57. PubMed ID: 20527890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future treatment of chronic hepatitis C.
    Keeffe EB
    Antivir Ther; 2007; 12(7):1015-25. PubMed ID: 18018759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic strategies for hepatitis C.
    Di Bisceglie AM; McHutchison J; Rice CM
    Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C: a new horizon.
    Chang KM
    Gastroenterology; 2006 Dec; 131(6):1667-8. PubMed ID: 17188957
    [No Abstract]   [Full Text] [Related]  

  • 40. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.